1 of 1
Story summary
- The U.S. Food and Drug Administration removed black box warnings from hormone replacement therapy for menopause on November 10, 2025, potentially increasing treatment access.
- The decision followed an expert panel review that criticized past studies for overstating risks.
- Dr. Marty Makary, a medical expert, argues hormone therapy can improve outcomes, especially when started before age 60.
- Caution remains for people with a history of reproductive cancers.
